Search

Your search keyword '"Laila Elias"' showing total 6 results
Start Over Author "Laila Elias"
6 results on '"Laila Elias"'

1. The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions

Author

Sunil Girish Iyer, Laila Elias, Michele Stanchina, and Justin Watts

Subjects
acute promyelocytic leukemia, all-trans retinoic acid (ATRA), arsenic trioxide (ATO), differentiation syndrome, disseminated intravascular coagulation (DIC), coagulopathy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The transformation of acute promyelocytic leukemia (APL) from an often fatal to highly curable cancer with long-term survival exceeding 90% is one of the greatest and most inspiring successes in oncology. A deeper understanding of the pathogenesis of APL heralded the introduction of highly effective therapies targeting the mutant protein that drives the disease, leading to the chemotherapy-free approach to cure almost all patients. In this review, we discuss the paradigm of treatment of APL in 2023, reinforce the high risk of early death without prompt initiation of treatment at first clinical suspicion, and dedicate a special focus to novel agents and future directions to improve cure rates and quality of life in patients affected by APL.

Published
2023
Full Text
View/download PDF

2. Use of treatment pathway improves neoadjuvant chemotherapy use in muscle-invasive bladder cancer

Author

Kassem S, Faraj, Anojan K, Navaratnam, Sarah, Eversman, Laila, Elias, Amit, Syal, Mark D, Tyson, and Erik P, Castle

Subjects
Aged, 80 and over, Male, Treatment Outcome, Urinary Bladder Neoplasms, Critical Pathways, Humans, Female, Neoplasm Invasiveness, Middle Aged, Neoadjuvant Therapy, Aged, Retrospective Studies
Abstract

To assess the trends of neoadjuvant chemotherapy (NAC) use since its introduction in our practice pathway in patients with cT2 + bladder cancer over a 20-year period.This is a retrospective review of patients with cT2 + bladder cancer who underwent RC between 01/01/1998 and 01/01/2018 that aimed to evaluate the trends of NAC use and associated after implementation of a multidisciplinary treatment pathway. Cohorts were stratified into eras: pre-NAC (1998-2007) to NAC eras (2008-2018). Univariate analysis was conducted using Chi-squared test and Kaplan-Meier estimates were used to evaluate survival.In 904 total patients who underwent RC, there were 493 with cT2 + UCC disease. The rate of NAC peaked at 84.2% in the most recent year of analysis in all patients and was 100% in cT2 + patients eligible for NAC. There was an increased rate of complete response (downstage to pT0) from 8.7% to 15.8% (p = 0.018) between the two eras. Unadjusted survival analysis revealed improved overall survival (OS) between eras with 5-year OS 53.2% vs. 42.7% and 10-year OS 42.7% vs. 26.4% in the NAC vs. pre-NAC cohorts, respectively (p = 0.016).In this review of 20 years of experience, we report a dramatic rise in the use of NAC after adoption of a multidisciplinary pathway that is associated with expected survival benefits.

Published
2020

3. Comparison of Open and Robot Assisted Radical Nephrectomy With Level I and II Inferior Vena Cava Tumor Thrombus: The Mayo Clinic Experience

Author

Laila Elias, Anojan Navaratnam, Kassem Faraj, Kyle Rose, Mark D. Tyson, Victor J. Davila, Amit Syal, Adyr A. Moss, William G. Eversman, Haidar M. Abdul-Muhsin, Samuel R. Money, Erik P. Castle, and William M. Stone

Subjects
Male, medicine.medical_specialty, Urology, medicine.medical_treatment, 030232 urology & nephrology, Vena Cava, Inferior, Inferior vena cava, Nephrectomy, 03 medical and health sciences, 0302 clinical medicine, Robotic Surgical Procedures, Renal cell carcinoma, Carcinoma, Medicine, Humans, Thrombus, Carcinoma, Renal Cell, Aged, Retrospective Studies, Univariate analysis, business.industry, Retrospective cohort study, Perioperative, Middle Aged, medicine.disease, Neoplastic Cells, Circulating, Hospitals, Kidney Neoplasms, Surgery, Treatment Outcome, medicine.vein, 030220 oncology & carcinogenesis, Female, business
Abstract

To compare the perioperative and oncologic outcomes associated with open radical nephrectomy with tumor thrombus (O-RNTT) vs robot assisted radical nephrectomy with tumor thrombus (RA-RNTT). Renal cell carcinoma with venous tumor thrombus has traditionally been managed through an open surgical approach. The robot assisted approach may offers improved perioperative outcomes compared to open, but there are few studies comparing these 2.We analyzed patients with renal cell carcinoma and inferior vena cava tumor thrombus between 1998 and 2018, comparing perioperative and oncologic outcomes of these patients with Level I and Level II thrombus. Cohorts were stratified by surgical approach: O-RNTT vs RA-RNTT. Univariate analysis was conducted using chi-squared test and t tests when appropriate. Kaplan-Meier estimates were used to evaluate survival.Twenty-seven patients were in the O-RNTT group, and 24 in the RA-RNTT group. Patients in the RA-RNTT group, compared to the O-RNTT group, demonstrated shorter length of stay (3 vs 7 nights, P = .03), lower estimate blood loss (450 vs 1800 mL, P.01), and lower transfusion rate (21% vs 82%, P.01). The RA-RNTT group had 26% fever complications compared to the open (17% vs 43%, P.01). There was no significant difference in estimated overall survival or recurrence-free survival between the O-RNTT and RA-RNTT groups.RA-RNTT produced a shorter length of stay, less transfusions, and a lower rate of complications with no significant difference in overall survival.

Published
2019

4. MP26-09 THE CONTEMPORARY USE OF NEOADJUVANT CHEMOTHERAPY PRIOR TO RADICAL CYSTECTOMY FOR UROTHELIAL CANCER: THE IMPACT OVER A 13 YEAR PERIOD

Author

Anojan Navaratnam, Michael Patton, Mark D. Tyson, Kyle Rose, Laila Elias, Sarah Eversman, Amit Syal, Kassem Faraj, Haidar Abdul-Muhsin, and Erik P. Castle

Subjects
Oncology, Cystectomy, Chemotherapy, medicine.medical_specialty, business.industry, Urology, medicine.medical_treatment, Internal medicine, Medicine, Urothelial cancer, Disease, Stage (cooking), business
Abstract

INTRODUCTION AND OBJECTIVES:The use of neoadjuvant chemotherapy (NAC) prior to cystectomy for urothelial cancer of the bladder is recommended for all patients with clinical stage(c) T2+ disease in ...

Published
2019
Full Text
View/download PDF

6. A celeridade nos processos de adoção: uma reflexão acerca da necessária desburocratização do processo = The swiftness in adoption process: a reflection about the necessary debureaucratization prosecution

Author

Mansur, Laila Elias and Silva, Carlos Alberto de Souza

Abstract

Submitted by Tiago Carvalho (tiagosc@stj.jus.br) on 2017-03-17T17:35:42Z No. of bitstreams: 2 celeridade_processos_adocao_mansur.pdf: 562234 bytes, checksum: 257cf58b24d559282ebad57fa99034bc (MD5) license.txt: 1239 bytes, checksum: c9b4c351324448672315a00808efb725 (MD5) Approved for entry into archive by Roberta Marins (rmarins@stj.jus.br) on 2017-03-21T17:13:40Z (GMT) No. of bitstreams: 2 license.txt: 1239 bytes, checksum: c9b4c351324448672315a00808efb725 (MD5) celeridade_processos_adocao_mansur.pdf: 562234 bytes, checksum: 257cf58b24d559282ebad57fa99034bc (MD5) Made available in DSpace on 2017-03-21T17:13:40Z (GMT). No. of bitstreams: 2 license.txt: 1239 bytes, checksum: c9b4c351324448672315a00808efb725 (MD5) celeridade_processos_adocao_mansur.pdf: 562234 bytes, checksum: 257cf58b24d559282ebad57fa99034bc (MD5) Previous issue date: 2017

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results